Here's Why You Should Hold Cigna Stock in Your Portfolio for Now

Cigna (CI) shares have outperformed the industry, rising 14.7% YTD, driven by growth in its Evernorth and Cigna Healthcare segments, which saw revenue increases of 16% and 9% respectively in Q1 2025. The company anticipates a minimum of $7.9 billion in adjusted operating income for 2025, supported by strategic partnerships and share repurchases totaling $2.6 billion year-to-date. However, investors should note Cigna's escalating benefit expenses, which rose 16% in Q1 2025, and its substantial $26.5 billion long-term debt, which could pressure margins and increase interest expenses.

Analysis

Cigna (CI) has demonstrated notable resilience with a 14.7% year-to-date share price increase, starkly outperforming the industry's 29.1% decline. This performance is underpinned by robust growth in its primary segments: Evernorth Health Services reported a 16% year-over-year revenue increase to $53.7 billion in Q1 2025, while Cigna Healthcare revenues grew 9% in the same period. The company's forward P/E ratio of 8.72X stands favorably below the industry average of 13.87X. Analysts project continued growth, with the Zacks Consensus Estimate for Cigna’s 2025 earnings at $29.68 per share, indicating an 8.6% year-over-year rise, and revenues at $257 billion for 2025, supported by 10 upward estimate revisions against one downward in the past month. Cigna anticipates its adjusted operating income to be a minimum of $7.9 billion in 2025 and has actively returned value to shareholders, repurchasing 8.2 million shares for $2.6 billion from the start of the year till May 1. However, significant headwinds persist. The company’s total benefits and expenses have escalated, with a year-over-year increase of 16% in the first quarter of 2025, contributing to margin pressure. Specifically, the medical cost ratio deteriorated by 230 basis points year-over-year to 82.2% in Q1 2025. Furthermore, Cigna carries a substantial long-term debt of $26.5 billion as of March 31, 2025, significantly higher than its cash balance of $8.3 billion, resulting in a net debt-to-capital ratio of 33.1%, which is above the industry’s average of 22.5%.

Key Decisions for Investors

• Given Cigna's strong revenue growth, outperformance relative to its industry, and active share repurchase program, investors might consider the current Zacks Rank #3 (Hold) as indicative of a balanced risk-reward profile at present.
• Investors should closely monitor the trend in total benefits and expenses and the medical cost ratio, as persistent increases could further erode margins and impact profitability despite top-line growth.
• The company's substantial debt load warrants careful attention; assess its ability to manage leverage and potential impacts on interest expenses and financial flexibility, especially in the context of its cash position.
• While Cigna's lower forward P/E ratio compared to the industry average suggests a potential valuation opportunity, this should be weighed against the aforementioned operational cost pressures and balance sheet leverage before making new investment decisions.